secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001824293-25-000053
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025
------------------------------------------------------------------

- Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.
- Cash and equivalents of $5.0M at Dec 31, 2024; runway only into Q2 2025 (through interim data).
- Phase 2a interim data for GRI-0621 in IPF expected Q2 2025; topline results Q3 2025.
- European patent granted for GRI-0803 and library of 500+ proprietary NKT cell modulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/0001824293-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/val-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001824293-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer